Cargando…

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels

Background: The role of statins in prostate cancer (PCa) remains unclear. Conflicting evidence has been found concerning risk reduction with the use of statins on biochemical recurrence (BCR). In this study, we evaluated whether statin use decreases the incidence of advanced PCa in males with elevat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijer, Dennie, van Moorselaar, R. Jeroen A., Vis, André N., Bijnsdorp, Irene V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678232/ https://www.ncbi.nlm.nih.gov/pubmed/31284686 http://dx.doi.org/10.3390/cancers11070953

Ejemplares similares

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2022)

Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels
por: Tamada, Tsutomu, et al.
Publicado: (2019)

Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients
por: Bijnsdorp, Irene V., et al.
Publicado: (2013)

Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles
por: Koppers-Lalic, Danijela, et al.
Publicado: (2016)

Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method
por: Bijnsdorp, Irene V., et al.
Publicado: (2017)

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
por: Bodar, Yves J.L., et al.
Publicado: (2022)

Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy
por: Liu, Xiaonan, et al.
Publicado: (2017)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
por: Kobayashi, Minoru, et al.
Publicado: (2023)

A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis
por: Bijnsdorp, I V, et al.
Publicado: (2012)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
por: Luining, Wietske I., et al.
Publicado: (2021)

Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
por: Yoneyama, Tohru, et al.
Publicado: (2021)

A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy
por: Iwamura, Hiromichi, et al.
Publicado: (2014)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2021)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110
por: Bijnsdorp, Irene V., et al.
Publicado: (2016)

PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study
por: Bruno, Salvatore M., et al.
Publicado: (2021)

Protein Complexes in Urine Interfere with Extracellular Vesicle Biomarker Studies
por: Wachalska, Magda, et al.
Publicado: (2016)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer?
por: Abd-Alazeez, Mohamed, et al.
Publicado: (2014)

Low Levels of Urinary PSA Better Identify Prostate Cancer Patients
por: Occhipinti, Sergio, et al.
Publicado: (2021)

Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study
por: Grelus, Alin, et al.
Publicado: (2017)

AB126. Impact of HMG-CoA reductase inhibitor (statin) use on serum PSA and prostate volume in BPH patients
por: Park, Heung Jae
Publicado: (2014)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging
por: Meijer, Dennie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qt4bmo47jjubcquniubap13lul